As of November 29, 2025, it is too early to definitively judge a century‑scale prediction about the United States experiencing a sustained biomanufacturing growth wave for “this century.”

What we can say so far (2020–2025):

• The U.S. government has clearly moved to elevate biomanufacturing:
  • In September 2022, the White House issued an Executive Order on Advancing Biotechnology and Biomanufacturing, explicitly aiming to expand the U.S. bioeconomy and domestic biomanufacturing capabilities.
  • Subsequent implementation reports and funding initiatives describe biotechnology and biomanufacturing as central to future U.S. industrial competitiveness, touching sectors like pharmaceuticals, agriculture, materials, and fuels.
• Private and public investments in biotech and bio‑industries have been large and growing through the early–mid 2020s (e.g., synthetic biology companies, biomanufacturing facilities, and government-backed innovation programs).

These developments support the near‑term part of Friedberg’s claim (a “big wave” of biomanufacturing emerging in the 2020s) and are directionally consistent with it becoming an important industrial pillar.

However, the prediction explicitly concerns the rest of the 21st century. Long‑term durability—whether biomanufacturing remains a major industrial pillar through the 2070s, 2090s, etc.—cannot be assessed from only five years of data. Technology shifts, policy reversals, competing industries, or unforeseen constraints could still alter this trajectory.

Because the key part of the claim is about a multi‑decade to century‑long outcome, and we currently have visibility into only the first few years, the correct status is:

• Result: inconclusive (too early to tell), though current evidence is consistent with the prediction’s early-stage trend.

(No specific web citations are included here to comply with your output-format requirement, but the reasoning is based on publicly available U.S. policy documents and industry investment trends from 2020–2025.)